Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 166

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves

Open access
Carnicelli, Anthony P., De Caterina, Raffaele, Halperin, Jonathan L., Renda, Giulia, Ruff, Christian T., Trevisan, Marco, Nordio, Francesco, Mercuri, Michele F., Antman, Elliott, Giugliano, Robert P. · 2017 · Circulation

Abstract

A trial fibrillation (AF) and valvular heart disease frequently coexist and independently increase mortality.1 Bioprosthetic valve implantation (surgical or transcatheter) is a common, increasingly utilized treatment for valvular heart disease. 2 Patients with AF and bioprosthetic valves require anticoagulation to prevent thromboembolic events.Non-vitamin K oral anticoagulants are safe and efficacious alternatives to vitamin K antagonists for anticoagulation in AF.However, guidelines recommend against using non-vitamin K oral anticoagulants in patients with bioprosthetic valves, citing a lack of supporting data.Only 1 of the first 3 warfarin-controlled pivotal non-vitamin K oral anticoagulants trials in AF included patients with bioprosthetic valves (n>80).3 The ENGAGE AF-TIMI 48 trial (Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation Thrombolysis in Myocardial Infarction 48), which compared edoxaban (a direct oral factor Xa inhibitor) to warfarin in patients with AF, 4 did not exclude patients with bioprosthetic valves, thus providing an opportunity to analyze this high-risk subgroup.ENGAGE AF-TIMI 48 randomized patients with AF and a CHADS 2 score (Congestive heart failure, Hypertension, Age ≥ 75 years, Diabetes mellitus, Stroke or TIA [2 points]) ≥2 to a once daily higher dose edoxaban regimen (60 mg), lower dose edoxaban regimen (30 mg), or warfarin (International Normalized Ratio target of 2.0-3.0).The edoxaban dose was reduced by 50% in patients with decreased clearance.Patients with a history of left-sided valvular heart disease, 5 including those with a history of aortic or mitral bioprosthetic valve implantation (either surgical or transcatheter) >30 days before randomization, were analyzed because right-sided valvular heart disease rarely causes stroke.The indication and date of bioprosthetic valve implantation were not collected.Patients with mechanical valves or moderate-severe mitral stenosis were excluded.The ENGAGE AF-TIMI 48 protocol and amendments were approved by the ethics committee at each participating center.All participants provided written informed consent.The study was registered with ClinicalTrials.gov(unique identifier: NCT00781391) and can be found at https://clinicaltrials.gov/ct2/show/ NCT00781391.In this prespecified analysis, we evaluated outcomes with edoxaban versus warfarin in patients with bioprosthetic valves enrolled in ENGAGE AF-TIMI 48.Primary end points included stroke or systemic embolic events (stroke/SEE), major bleeding (per the International Society for Thrombosis and Haemostasis definition), and the primary net clinical outcome (stroke/SEE, major bleeding, death).Secondary composite end points included ischemic stroke/SEE, major adverse cardiac events (myocardial infarction, stroke, or cardiovascular death), and the composite of stroke/SEE, all-cause mortality, and life-threatening or fatal bleeding (alternative net clinical outcome).An independent, blinded clinical end point committee adjudicated all clinical end points as defined in the main trial.Baseline patient characteristics were described, and hazard ratios (HRs) for each end point comparing higher and lower dose edoxaban to warfarin were calculated.Of 21 105 patients enrolled in the main trial, 191 (0.9%) had previous bioprosthetic valve implantation (n=131 [68.6%] mitral, n=60 [31.4%] aortic).The median follow-up

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.116.026714

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 166

Metadata

Authors
Carnicelli, A. P., De Caterina, R., Halperin, J. L., Renda, G., Ruff, C. T., Trevisan, M., Nordio, F., Mercuri, M. F., Antman, E., & Giugliano, R. P.
Venue
Circulation
Published
2017-03-28
Volume
135
Issue
13
Pages
1273-1275
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2588405059
Cited by
166
References
2
FWCI
12.68
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. https://app.cochat.ai/papers/10.1161/circulationaha.116.026714
The paper
Carnicelli, A. P., De Caterina, R., Halperin, J. L., Renda, G., Ruff, C. T., Trevisan, M., Nordio, F., Mercuri, M. F., Antman, E., & Giugliano, R. P. (2017). Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. Circulation. https://doi.org/10.1161/circulationaha.116.026714

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.